4-D (psychedelic)

4-D

Clinical data
Other names	Mescaline-D3; 4-Trideuteromethoxy-3,5-methoxyphenethylamine; 4-Trideuteromescaline
Routes of administration	Oral
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None
Pharmacokinetic data
Duration of action	12 hours
Identifiers
IUPAC name 1-[3,5-dimethoxy-4-(2H3)methoxyphenyl]propan-2-amine
CAS Number	1020518-87-9 N
ChemSpider	23553050 Y
UNII	46N9S93HNE
Chemical and physical data
Formula	C11H14D3NO3
Molar mass	214.278 g·mol−1
3D model (JSmol)	Interactive image
SMILES [2H]C([2H])([2H])OC1=C(OC)C=C(CCN)C=C1OC
InChI InChI=1S/C11H17NO3/c1-13-9-6-8(4-5-12)7-10(14-2)11(9)15-3/h6-7H,4-5,12H2,1-3H3/i3D3 Y Key:RHCSKNNOAZULRK-HPRDVNIFSA-N Y
NY (what is this?)  (verify)

4-D, also known as 4-trideuteromethoxy-3,5-methoxyphenethylamine or as 4-trideuteromescaline, is a lesser-known psychedelic drug of the scaline family. It is one of the few drugs that bears deuterium. It is a deuterated analog of mescaline. It may be prepared either as a sulfate salt or a hydrochloride salt. 4-D was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage is listed as approximately 200–400 mg for the sulfate salt, and 178–356 mg for the hydrochloride salt. 4-D lasts for approximately 12 hours. It causes closed-eye visuals, mild open-eye visuals, color distortion, and mydriasis. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-D. The drug does not seem to be a controlled substance in Canada as of 2025.

See also

• Scaline
• Beta-D (β-dideuteromescaline)